{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:17Z","timestamp":1787870297960,"version":"build-2784847793"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jcv.2021.105032","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:12:22Z","timestamp":1637633542000},"page":"105032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review"],"prefix":"10.1016","volume":"146","author":[{"given":"Olumuyiwa E","family":"Ariyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2021.105032_bib0001","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in Adults: 2016 recommendations of the international antiviral society-USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.jcv.2021.105032_bib0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","author":"Saag","year":"2018","journal-title":"JAMA - J. Am. Med. Assoc., NIH Public Access"},{"key":"10.1016\/j.jcv.2021.105032_bib0003","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1001\/jama.2019.2591","article-title":"Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force","volume":"321","author":"Chou","year":"2019","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.jcv.2021.105032_bib0004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QAI.0000000000001654","article-title":"Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate\/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals","volume":"78","author":"Jotwani","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2021.105032_bib0005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin. Infectious Diseases."},{"key":"10.1016\/j.jcv.2021.105032_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.jcv.2021.105032_bib0007","doi-asserted-by":"crossref","unstructured":"F. Altice, O. Evuarherhe, S. Shina, G. Carter, A.C. Beaubrun, Adherence to HIV treatment regimens: systematic literature review and meta-analysis, Patient Preference and Adherence. 13 (2019) 475\u2013490. 10.2147\/PPA.S192735.","DOI":"10.2147\/PPA.S192735"},{"key":"10.1016\/j.jcv.2021.105032_bib0008","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3389\/fphar.2017.00831","article-title":"Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations","volume":"8","author":"Iacob","year":"2017","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.jcv.2021.105032_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41687-019-0124-3","article-title":"A review of HIV-specific patient-reported measures of perceived barriers to antiretroviral therapy adherence: what themes are they covering?","volume":"3","author":"Engler","year":"2019","journal-title":"J. Patient-Reported Outcomes"},{"key":"10.1016\/j.jcv.2021.105032_bib0010","doi-asserted-by":"crossref","first-page":"21166","DOI":"10.7448\/IAS.19.1.21166","article-title":"Barriers and facilitators of interventions for improving antiretroviral therapy adherence: a systematic review of global qualitative evidence: A","volume":"19","author":"Ma","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jcv.2021.105032_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jcv.2021.105032_bib0012","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.jcv.2021.105032_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"M\u00fcller","year":"2011","journal-title":"Eur. J. Pharm.Biopharm."},{"key":"10.1016\/j.jcv.2021.105032_bib0014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2018.04.014","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","volume":"138","author":"Gao","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jcv.2021.105032_bib0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.actbio.2018.04.045","article-title":"Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir\/ritonavir antiretroviral combination","volume":"74","author":"Augustine","year":"2018","journal-title":"Acta. Biomater."},{"key":"10.1016\/j.jcv.2021.105032_bib0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/nnm.16.1","article-title":"Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV\/AIDS","volume":"11","author":"Shao","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jcv.2021.105032_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1358\/dot.2019.55.1.2895651","article-title":"Ibalizumab for the treatment of multidrug-resistant HIV-1 infection","volume":"55","author":"Rizza","year":"2019","journal-title":"Drugs of Today"},{"key":"10.1016\/j.jcv.2021.105032_bib0018","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2021.105032_bib0019","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: first Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jcv.2021.105032_bib0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000470","article-title":"Antiretroviral implants for treatment and prevention of HIV infection","volume":"13","author":"Flexner","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0021","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","article-title":"Acceptability and use of a dapivirine vaginal ring in a phase III trial","volume":"31","author":"Montgomery","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","article-title":"Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension","volume":"292","author":"Mc Crudden","year":"2018","journal-title":"J. Controlled Release\u00a0: Official J. Controlled Release Society"},{"key":"10.1016\/j.jcv.2021.105032_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","article-title":"Clinical pharmacology in HIV therapy","volume":"14","author":"Atta","year":"2019","journal-title":"Clin. J. Am. Society of Nephrol."},{"key":"10.1016\/j.jcv.2021.105032_bib0024","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","article-title":"Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults","author":"Spreen","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2021.105032_bib0025","article-title":"GSK1265744 (Cabotegravir, CAB) for named patient\/compassionate use in HIV","author":"Healthcare","year":"2018","journal-title":"ClinicalTrials.Gov"},{"key":"10.1016\/j.jcv.2021.105032_bib0026","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1310\/hct1405-192","article-title":"Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor","volume":"14","author":"Spreen","year":"2013","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.jcv.2021.105032_bib0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2017.10.017","article-title":"Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat","volume":"268","author":"Jucker","year":"2017","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.jcv.2021.105032_bib0028","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","author":"Spreen","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2021.105032_bib0029","doi-asserted-by":"crossref","unstructured":"M. Markowitz, I. Frank, R.M. Grant, K.H. Mayer, R. Elion, D. Goldstein, C. Fisher, M.E. Sobieszczyk, J.E. Gallant, H. Van Tieu, W. Weinberg, D.A. Margolis, K.J. Hudson, B.S. Stancil, S.L. Ford, P. Patel, E. Gould, A.R. Rinehart, K.Y. Smith, W.R. Spreen, Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial, The Lancet HIV. 4 (2017) e331\u2013e340. 10.1016\/S2352-3018(17)30068-1.","DOI":"10.1016\/S2352-3018(17)30068-1"},{"key":"10.1016\/j.jcv.2021.105032_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.jcv.2021.105032_bib0031","article-title":"For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men - Full Text View","year":"2021","journal-title":"ClinicalTrials.gov, (n.d.)"},{"key":"10.1016\/j.jcv.2021.105032_bib0032","unstructured":"The HIV Prevention Trials Network, Prevention Now, (n.d.). https:\/\/www.hptn.org\/research\/studies\/hptn083 (accessed November 16, 2020)."},{"key":"10.1016\/j.jcv.2021.105032_bib0033","article-title":"Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing","year":"2021","journal-title":"HIV acquisition in women, (n.d.)"},{"key":"10.1016\/j.jcv.2021.105032_bib0034","first-page":"15","article-title":"Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants","author":"Smith","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.jcv.2021.105032_bib0035","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkw042","article-title":"A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges","volume":"71","author":"Kovarova","year":"2016","journal-title":"J. Antimicrobial Chemotherapy"},{"key":"10.1016\/j.jcv.2021.105032_bib0036","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1358\/dot.2019.55.5.2962947","article-title":"Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy","volume":"55","author":"Fida","year":"2019","journal-title":"Drugs of Today"},{"key":"10.1016\/j.jcv.2021.105032_bib0037","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcv.2021.105032_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2019.04.007","article-title":"A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: a proof-of-concept study","volume":"167","author":"Mandal","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2021.105032_bib0039","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jcv.2021.105032_bib0040","article-title":"FDA-Approved HIV Medicines | Understanding HIV\/AIDS","year":"2021","journal-title":"AIDSinfo, (n.d.)"},{"key":"10.1016\/j.jcv.2021.105032_bib0041","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.jcv.2021.105032_bib0042","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.jcv.2021.105032_bib0043","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hiv.12247","article-title":"Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers","volume":"16","author":"Verloes","year":"2015","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2021.105032_bib0044","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.jcv.2021.105032_bib0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COH.0000000000000164","article-title":"Formulation and pharmacology of long-acting rilpivirine","volume":"10","author":"Williams","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0046","first-page":"61","article-title":"Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals","author":"Aouri","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2021.105032_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.jcv.2021.105032_bib0048","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/aid.2017.0135","article-title":"Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 subtype C-infected patients failing nevirapine or efavirenz-based combination antiretroviral therapy in botswana","volume":"34","author":"Diphoko","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jcv.2021.105032_bib0049","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE)","volume":"15","author":"Margolis","year":"2015","journal-title":"A randomised, phase 2b, dose-ranging trial, The Lancet Infectious Diseases"},{"key":"10.1016\/j.jcv.2021.105032_bib0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","author":"Swindells","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2021.105032_bib0051","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection","author":"Orkin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2021.105032_bib0052","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2021.105032_bib0053","unstructured":"ViiV, Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV, (n.d.). https:\/\/viivhealthcare.com\/en-gb\/media\/press-releases\/2020\/march\/viiv-healthcare-announces-first-global-regulatory-approval-of-ca\/(accessed May 7, 2021)."},{"key":"10.1016\/j.jcv.2021.105032_bib0054","article-title":"HIV recommended for approval","year":"2021","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.jcv.2021.105032_bib0055","article-title":"FDA Approves First Extended-Release","year":"2021","journal-title":"Injectable Drug Regimen for Adults Living with HIV | FDA"},{"key":"10.1016\/j.jcv.2021.105032_bib0056","article-title":"Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","year":"2019","journal-title":"Full Text View - ClinicalTrials.gov"},{"key":"10.1016\/j.jcv.2021.105032_bib0057","article-title":"Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable","author":"Janssen","year":"2019","journal-title":"HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy"},{"key":"10.1016\/j.jcv.2021.105032_bib0058","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0253-7613.96296","article-title":"Antiretroviral drugs: critical issues and recent advances","volume":"44","author":"Desai","year":"2012","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.jcv.2021.105032_bib0059","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cpt.1393","article-title":"Contemporary drug\u2013drug interactions in HIV treatment","volume":"105","author":"Devanathan","year":"2019","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.jcv.2021.105032_bib0060","unstructured":"H. Crauwels, R.P.G. van Heeswijk, M. Stevens, A. Buelens, S. Vanveggel, K. Boven, R. Hoetelmans, Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine., AIDS Rev. 15 (n.d.) 87\u2013101. (2010)."},{"key":"10.1016\/j.jcv.2021.105032_bib0061","first-page":"61","article-title":"Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects","author":"Ford","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2021.105032_bib0062","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/COH.0000000000000495","article-title":"Challenges of TB and HIV co-treatment: updates and insights","volume":"13","author":"Tornheim","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0063","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12879-016-1629-5","article-title":"No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects","volume":"16","author":"Ross","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jcv.2021.105032_bib0064","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00228-016-2020-6","article-title":"Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation","volume":"72","author":"Song","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jcv.2021.105032_bib0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/pharmaceutics3040745","article-title":"Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management","volume":"3","author":"Rathbun","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jcv.2021.105032_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir\u00a0+\u00a0rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcv.2021.105032_bib0067","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/15284336.2018.1511346","article-title":"Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial","volume":"19","author":"Murray","year":"2018","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.jcv.2021.105032_bib0068","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.contraception.2013.11.008","article-title":"Members of the rakai health sciences program sayana press study team, preference for sayana\u00ae press versus intramuscular depo-provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial","volume":"89","author":"Polis","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.jcv.2021.105032_bib0069","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/COH.0000000000000219","article-title":"The promise and pitfalls of long-acting injectable agents for HIV prevention","volume":"11","author":"Landovitz","year":"2016","journal-title":"Curr Opin. HIV AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COH.0000000000000160","article-title":"Long-acting rilpivirine for HIV prevention","volume":"10","author":"Jackson","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jcv.2021.105032_bib0071","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.jcv.2021.105032_bib0072","article-title":"ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months","author":"Healthcare","year":"2019","journal-title":"GSK"},{"key":"10.1016\/j.jcv.2021.105032_bib0073","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s40265-017-0820-3","article-title":"Elsulfavirine: first Global Approval","volume":"77","author":"Al-Salama","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jcv.2021.105032_bib0074","article-title":"Pre-clinical development of elsulfavirine\/VM1500A long","author":"Rogovoy","year":"2017","journal-title":"Acting Injectable Formulations"},{"key":"10.1016\/j.jcv.2021.105032_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2019.04.010","article-title":"Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV","volume":"167","author":"Kudalkar","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.jcv.2021.105032_bib0076","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/AAC.00267-13","article-title":"Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy","volume":"57","author":"Gautam","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2021.105032_bib0077","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2018.04.009","article-title":"Towards a Maraviroc long-acting injectable nanoformulation","volume":"138","author":"Tatham","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jcv.2021.105032_bib0078","article-title":"The discovery of novel potent HIV capsid inhibitors with long-acting potential","author":"Winston","year":"2017","journal-title":"Conference on Retroviruses and Opportunistic Infections"},{"key":"10.1016\/j.jcv.2021.105032_bib0079","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy210.548","article-title":"GS-CA2: a novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function displays nonclinical pharmacokinetics supporting long-acting potential in humans","volume":"5","author":"Zheng","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jcv.2021.105032_bib0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/HIV.S184642","article-title":"Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential","volume":"11","author":"Fernandez","year":"2019","journal-title":"HIV\/AIDS - Research and palliative care"},{"key":"10.1016\/j.jcv.2021.105032_bib0081","first-page":"75","article-title":"Long-Acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective","volume":"40","author":"Rusconi","year":"2017","journal-title":"N. Microbiologica"},{"key":"10.1016\/j.jcv.2021.105032_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653221002997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653221002997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:15:01Z","timestamp":1761362101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653221002997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":82,"alternative-id":["S1386653221002997"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2021.105032","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2021.105032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105032"}}